Komori
Kaken Pharmaceutical (4521) · InitiativeFirst stated

Joint development of software as a medical device in orthopedics

First written in FY2025-H1. . Latest entry: FY2025-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Joint development of software as a medical device in orthopedicsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2025-H1First statedAnnual report

    「The Company entered into a feasibility study agreement with クロスメッド株式会社 for the development of software as a medical device for the treatment of orthopedic diseases.」

    The Company entered into a feasibility study agreement with クロスメッド株式会社 to develop software as a medical device for orthopedic diseases. This is a new initiative for the joint development of digital applications and digital products in orthopedics, as set out in the Long-Term Management Plan 2031.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.